Pfizer offers data on pain relief drug

Pfizer Inc. released results Thursday from three late-stage studies of its experimental medication ALO-02 that the company said showed the drug's administration led to a significant improvement in lower-back pain relief while indicating less chance of abuse.

Data on the extended-relief capsules, a combination of oxycodone hydrochloride and naltrexone hydrochloride, were presented at the meeting of the American Pain Society in Tampa, Fla.

The data were from studies of people with moderate to severe back pain as well as recreational opioid users who, comparing to oxycodone, indicated feeling less high and experiencing less enjoyment when snorting or ingesting the drug.


Loading comments...
Hide Comments